Vedant Shah

Dr. Vedant Shah


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2023 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Open access
PDF file
VSVedant Shah
Vedant Shah
HPHarsh Patel
Harsh Patel
JOJaykumar Oza
Jaykumar Oza
PPPalak Patel
Palak Patel
HRHaripriya Radhakrishnan
Haripriya Radhakrishnan
SSSaketh Palsamudram Shekar
Saketh Palsamudram Shekar
COVID-19 usually presents with classic signs and symptoms, but it can involve multiple systems in atypical cases. SARS-CoV-2 has a complex interaction with the host immune system leading to atypical manifestations. In our case, a 32-year-old male patient presented with fatigue, sores on hands and feet, headache, productive cough with blood-tinged mucus, conjunctival hyperemia, purpuric rash on hands and feet, and splinter hemorrhages of fingernails for 2 weeks. The patient’s SARS-CoV-2 antigen and PCR test were positive. Chest X-ray showed mixed density perihilar opacities in both lungs. Computed tomography of the chest showed extensive airspace opacities in both lungs, suggesting COVID-19 multifocal, multilobar pneumonitis. A renal biopsy indicated limited thrombotic microangiopathy and tubulointerstitial nephritis, for which he was started on steroids, and his renal functions gradually improved. He tested positive for C-ANCA during an immune workup. He was discharged with a steroid taper for nephritis. Once the taper reached less than 10 mg/day, he developed acute scleritis and a new pulmonary cavitary lesion of 6 cm. The biopsy via bronchoscopy revealed acute inflammatory cells with hemosiderin-laden macrophages. He was restarted on systemic steroids for scleritis after failing topical steroids, which incidentally also reduced the size of the cavitary lesion, indicating an immune component. Our case demonstrates the involvement of kidneys and vasculitis of the skin, sclera, and lungs by COVID-19. The patient’s symptoms were not explained by any diseases other than COVID-19. Atypical cases of COVID-19 disease with multifocal systemic symptoms involving the skin, sclera, lungs, and kidneys should be high on differentials. Early recognition and intervention may decrease hospital stays and morbidity.

10 November 2023 in The Journal of Liquid Biopsy
Verified
Journal Article
Open access
UZUrvi Zala
Urvi Zala
RPRushi Patel
Rushi Patel
VPViraj Panchal
Viraj Panchal
JCJoy Chaudhari
Joy Chaudhari
VSVedant Shah
Vedant Shah
ASAbhi Shah
Abhi Shah
One of the main techniques for diagnosing lung cancer is still tissue biopsy. The more recent liquid biopsy technique includes the assessment of fragments of cfDNA, ctDNA, and CTCs, which are released by tumour cells and act as biomarkers. After compiling information from the existing literature, we conducted a statistical analysis to evaluate the prognosis and recurrence of NSCLC post-treatment using ctDNA levels. Based on predefined inclusion and exclusion criteria, published studies between 2000 and 2022 from electronic databases with statistical data on ctDNA levels for NSCLC were included. Then, using PRISMA guidelines, we carried out a systematic review of those studies. A total of 7 studies were included in the analysis, and we found a correlation of ctDNA levels for determination of prognosis and recurrence after treatment in NSCLC. Meta-analysis was performed using RevMan version 5.4. A P-value of less than 0.05 was considered significant. Studies were divided into three groups: three months post-surgery. Analysis showed that in <1-week post-surgery group, ctDNA-negative post-treatment detection had an HR of 4.85 (95 % CI: 2.41 to 9.77; p= three months group, with HR of 5.27 (95 % CI: 3.62 to 7.67; p=<0.00001, I2 = 11 %) and HR of 6.62 (95 % CI: 2.85 to 15.35; p=<0.0001, I2 = 64 %) respectively. According to our meta-analysis, patients with NSCLC who were ctDNA negative after surgery had a significantly longer recurrence-free survival than those who were ctDNA positive. As a result, liquid biopsy used to measure ctDNA levels is a useful non-invasive technique to assess the prognosis in such patients. The early detection of recurrence may also allow timely therapeutic intervention, leading to better outcomes.

17 October 2023 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
ASAbhi Shah
Abhi Shah
VPViraj Panchal
Viraj Panchal
VSVedant Shah
Vedant Shah
BVBhavya Vyas
Bhavya Vyas
HPHarshank Patel
Harshank Patel
JCJoy Chaudhari
Joy Chaudhari

14 August 2023 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
VSVedant Shah
Vedant Shah
HPHarsh Patel
Harsh Patel
NPNeel Patel
Neel Patel
JOJaykumar Oza
Jaykumar Oza
VPViraj Panchal
Viraj Panchal
YPYashash D. Pathak
Yashash D. Pathak

28 August 2024 in International Journal of Basic & Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MRMehak Roy
Mehak Roy
ASAbhi Shah
Abhi Shah
SBSubham Bhowmik
Subham Bhowmik
IPIshita Panchal
Ishita Panchal
VPViraj Panchal
Viraj Panchal
SBSanket Bharadwaj
Sanket Bharadwaj
Vonoprazan a competitive potassium acid blocker (P-CAB) has been gaining traction compared to the use of traditional PPIs for the treatment of GERD and other acid-related disorders. We aim to review its comparative edge over the other widely used PPIs and its combination therapies in this article. It is also emerging to show superiority in mucosal and clinical healing rates in the already published literature. The mechanism of action of vonoprazan involves the antagonism of potassium channels present in parietal cells, thereby inhibiting gastric acid secretion. This distinctive mode of action effectively suppresses acid secretion in gastroesophageal reflux disease (GERD) and erosive esophagitis. For clinical usage, 20 mg of vonoprazan has been reported to be more effective in the management of acid-related disorders compared to conventional PPIs. This article underscores the need for continued research to fully elucidate the potential of vonoprazan in managing acid-related disorders, particularly in populations beyond Japan where its utility remains to be fully explored. It also aims to enlighten healthcare providers regarding its usage in the management of acid-related gastrointestinal disorders by providing insights into its clinical utility, practical considerations, & effective drug combinations eventually ameliorating patient outcomes and quality of life.

26 November 2023 in Cureus
Verified
Journal Article
Open access
PDF file
NPNeel Patel
Neel Patel
HMHamza Mirza
Hamza Mirza
PBPayal Bai
Payal Bai
VSVedant Shah
Vedant Shah
HPHarsh Patel
Harsh Patel
SOSri J Obulareddy
Sri J Obulareddy
Hematological disorders pose a diagnostic challenge due to overlapping clinical features, as demonstrated by the difficulty in differentiating between aplastic anemia (AA) and primary myelofibrosis (PM). Myeloproliferative disorders, characterized by aberrant proliferation of bone marrow stem cells, present complexities in diagnosis, often requiring a comprehensive evaluation to distinguish between disorders with similar manifestations. The distinctions between myelofibrosis and AA lie not only in clinical presentations but also in genetic and molecular markers, necessitating a nuanced diagnostic approach. We present a case of a 37-year-old male initially diagnosed with myelofibrosis based on a history of pancytopenia, warm submandibular and submental swelling, and negative BCR-ABL and JAK2 mutations. Further examination revealed empty fragmented cells, hypoplastic bone marrow, and suppressed erythropoiesis and myelopoiesis. Subsequent core biopsy showed increased megakaryocytes, prompting a revised diagnosis of AA. This case underscores the importance of a meticulous diagnostic journey, incorporating physical examination, genetic testing, and advanced imaging to unravel the complexities of hematological disorders. The intricacies of this case prompt a reevaluation of diagnostic paradigms, highlighting the limitations of relying solely on specific mutations for diagnosis. The absence of BCR-ABL and JAK2 mutations in AA raises questions about its genetic landscape, necessitating further exploration. Immunological considerations, given the immune-mediated nature of AA, provide a foundation for future research into immune dysregulation and potential therapeutic interventions. The clinical management challenges posed by AA underscore the need for personalized treatment strategies, guided by a deeper understanding of its underlying pathophysiology. Advanced imaging techniques, in conjunction with traditional diagnostic methods, emerge as crucial tools for enhancing diagnostic accuracy in hematological disorders. This case serves as a paradigm for ongoing medical education, multidisciplinary collaboration, and innovative approaches in the evolving landscape of hematology, emphasizing the imperative for continuous refinement in diagnostic strategies and patient care.